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Renal Sympathetic Denervation In Patients With Resistant Hypertension -
Inducing An Immediate And Persisting 24h Ambulatory Blood Pressure (ABPM)
Reduction – Results From The Halle-RDN-Registry
Alexander Plehn1, Sebastian Dietz1, Henning Lemm1, Maria Leuthold1,
Silke Markau1, Daniel Medenwald1, Therese Schubert1, Alexander Vogt1,
Karl Werdan1
1Martin Luther University Halle-Wittenberg, Halle, Germany
Background: Catheter-based renal sympathetic denervation (RDN) has shown to
signiﬁcantly reduce blood pressure (BP) in patients with resistant hypertension. So far,
current available data are almost entirely derived from ofﬁce-based blood pressure
measurements (OBPM) with only few data basing on more reliable 24h ambulatory
blood pressure monitoring (ABPM).
Methods: Our study carefully investigated the ABPM response to RDN in a cohort
of 181 consecutively treated patients with resistant hypertension. Baseline values
included a mean age of 63 9.6 years, BMI of 31.9 5.8 Kg/m2, 48% women,
48% diabetic, 19% coronary artery disease and 5.7 1.8 antihypertensive medi-
cations. A 24h BP monitoring was recorded in every patient 24h before as well as
24h, 3, 6 and 12 months after RDN. BP readings were then averaged according
to daytime (7:00am-22:00pm), nighttime (22:00pm-7:00am) and 24 hours inter-
vals. All data were statistically analyzed using mixed models with repeated
measurements.
Results: In treated patients averaged systolic 24h BP was reduced by 10.341.32
mmHg (p<0.001; n 181) during the ﬁrst 24 hours. Systolic blood pressure reduction
appeared to be much higher at daytime (13.111.4 mm HG; p<0.001) compared to
nighttime (5.31.46 mm Hg; p¼0.0016) which most likely reﬂects the physiologi-
cally higher sympathetic activity at daytime. A concordant effect on diastolic BP was
observed: 6.870.76 mmHg (p<0.001). Systolic BP reduction sustained at 3
(5.631.48 mm Hg, p<0.005, n 147), 6 (4.871.5 mm Hg, p¼0.0014, n 136) and 12
months (7.591.82 mm Hg, p<0.001, n 101) without further decrease – on the
contrary a slight relapse to higher BP was seen.
Conclusions: In patients with resistant hypertension, RDN leads to an immediate and
persisting reduction of systolic and diastolic ABPM. Compared to OBPM data,
ABPM effects are expectedly less pronounced. A gradual drop in BP up to 6 months
was not seen. On the contrary a slight compensation of BP reduction was observed
after the initial drop and the 3, 6 and 12 months follow-ups. RDN may seem to
provide an acute as well as chronic therapeutic option to hypertensive Patients at risk.
TCT-494
Renal sympathetic denervation reduces blood pressure in patients with less
distinct resistant hypertension
David Sinning1, Heinz-Peter Schultheiss1, Michael Gross1
1Charité - Universitätsmedizin Berlin, Berlin, Germany
Background: Hypertension is highly prevalent and a major risk factor for coro-
nary artery disease, myocardial infarction, and stroke. Approximately 5-10% of
patients with high blood pressure are resistant to drug treatment. In these patients,
renal denervation (RD) offers an invasive approach to target the renal sympathetic
nerves and to hereby reduce blood pressure. To date, the efﬁcacy of RD has been
shown in patients with resistant hypertension and a systolic blood pressure (SBP)
 160mmHg ( 150mmHg for diabetes type 2 patients), despite treatment with
at least 3 antihypertensive drugs (including a diuretic). We therefore investigated
the effect of RDN on blood pressure in patients with less distinct resistant
hypertension.
Methods: Eligible patients were older than 18 years and had resistant hypertension
with an SBP of  135mmHg in the presence of at least 3 antihypertensive drugs
(including a diuretic). We investigated 20 patients and performed RDN using the
Simplicity catheter (Ardian, Palo Alto, California). Up to 8 ablations at 8 watt for 2
minutes were performed in both renal arteries. Blood pressure was measures at
baseline, at 3-month follow-up, and at 6-month follow-up.
Results: The mean age in the study population was 65  8.2 years. On average,
patients were taking 5.1 different antihypertensive drugs. The mean SBP was
148mmHg ( 10mmHg) at baseline. RD signiﬁcantly reduced SBP (-14.2mmHg at 3-
month follow-up, p¼0.016, and -22mmHg at 6-month follow-up, p¼0.014). Diastolic
blood pressure (75  8mmHg at baseline) did not change signiﬁcantly.
Conclusions: In patients with resistant hypertension and a SBP  135mmHg despite
treatment with at least 3 antihypertensive drugs, we demonstrate that RD is feasible
and signiﬁcantly reduces SBP. To achieve blood pressure treatment goals, RD should
therefore be taken into therapeutic considerations also in these patients. Further studies
are needed to investigate possible prognostic beneﬁts.
TCT-495
Novel Use of Micro-Infusion Catheter for Site-Speciﬁc Delivery of Local
Anesthetic Agent for Pain Control in Renal Sympathetic Denervation – First-in-
Man Experience
Simon C. C. Lam1, Stefan C. Bertog1, Sameer Gafoor1, Jennifer Franke1,
Laura Vaskelyte1, Ilona Hofmann1, Horst Sievert1
1CardioVascular Center Frankfurt, Frankfurt, GermanyJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrBackground: Current strategy for pain control in renal denervation includes intra-
venous administration of medications such as morphine and midazolam, which is
often not fully effective and is associated with potential side effects.
Methods: The Bullfrog Micro-Infusion Catheter (Mercator MedSystems, CA, USA)
consists of a perpendicular microneedle which is contained within a semi-rigid
polymer actuator. It can be introduced to the target renal artery over a 0.014" guide
wire prior to the denervation sequences on each side. A compliant stabilizing balloon
inﬂates to provide a force opposite the needle tip for proper seating of the needle,
through which anesthetic agent can be delivered to the adventitia and perivascular
tissue. A 1:1 mixture of 1% Lidocaine and intravenous contrast was used for localized
injection. Adequacy of agent delivery was determined by the presence of circumfer-
ential contrast distribution around the renal artery on ﬂuoroscopy.Results: Site-speciﬁc delivery of anesthetic agent was performed in 4 patients
undergoing renal denervation (3 radiofrequency-based and 1 ultrasound-based). Low
dose midazolam was given for 1 patient at the start of the procedure. No intravenous
midazolam or morphine was necessary for the remaining patients. No denervation-
speciﬁc pain was reported. Final renal angiography showed no signiﬁcant spasm or
dissection. All patients were discharged on the following day.
Conclusions: Site-speciﬁc administration of anesthetic agent may be a feasible
strategy to achieve optimal pain control in patients undergoing renal denervation for
treatment-resistant hypertension.
TCT-496
Impact of Criteria Stringency on Eligibility for Renal Denervation in
Hypertensive Outpatients
Salim Hayek1, Mahmoud Abdou1, Kobina Wilmot1, Benjamin DeMoss1,
Juan M. Ortega-Legaspi1, Anjan Deka1, Aalok Patel1, Sandeep Krishnan1,
Chandan Devireddy1
1Emory University, Atlanta, GA
Background: Renal denervation (RDN) has been shown to be safe and effective in
reducing blood pressure in select patients with resistant hypertension. Upcoming trials
aim to examine its use for more moderate manifestations of resistant hypertension. We
sought to determine the impact of broadening the eligibility criteria used in prior RDN
studies on the number of patients who could be eligible for RDN, and to compare the
clinical characteristics of RDN eligible versus non-eligible hypertensive patients in
a ﬁxed population of hypertensive outpatients.
Methods: We applied methodologic criteria from the SYMPLICITY HTN-3 study to
consecutive hypertensive outpatients presenting to an academic cardiology clinic to
identify patients eligible for RDN. Inclusion criteria were as follows: age >18 and
<80 years old, systolic BP> 60, on 33 anti-hypertensive medications at maximal
doses of which one was a diuretic, and creatinine clearance >45. We then examined
the impact on eligibility for RDN of including patients with systolic BP>140 and
creatinine clearance>30. Patients with renal arterial stenosis, or noncompliance were
excluded. Demographic and clinical characteristics of patients were compared
between those who did and did not meet criteria for RDN.
Results: We identiﬁed 1756 hypertensive outpatients; they were predominantly male
(54.9%) and white (53.2%), had a mean age of 66.612.6 years, and a BMI of
30.110.8 kg/m2. Only 22 of these patients (1.3%) would be eligible for RDN under
SYMPLICITY HTN-3 criteria. Among these patients, 16 (72.2%) were female and 20
(90.9%) were black, with a mean age of 68.910.4 and BMI of 33.26.8. Expanding
eligibility for RDN to include patients with SBP>140 and CrCl>30 lead to a near
three-fold increase in eligible patients (53 patients or 3.0%).
Conclusions: Patients meeting criteria for RDN based on existing published studies
represent an exceedingly small proportion of the total hypertensive population.
Broadening inclusion criteria, while still only relevant to only a small proportion of the
total hypertensive population, but a 375% increase over what prior studies would
predict.
TCT-497
Arterial Media Preservation Associated with The Paradise Ultrasound Renal
Denervation System: A Next generation Approach for Treating Resistant
Hypertension
Elena Ladich1, Leslie Coleman2, Vincent Cabane3, Kenichi Sakakura1,
Fumiyuki Otsuka1, Peter Markham4, Renu Virmani1
1CVPath Institute, Inc., Gaithersburg, MD, 2ReCor Medical, Menlo Park, CA, 3ReCor
Medical, Paris, France, 4CBSET Inc., Lexington, MAacts/POSTER/Renal Denervation B151
Parameter
Symplicity HTN 2
RDN group (n=52)
Luebeck RDN Registry
(N =79)
Age in years 58 + 12 63 + 11
Body Mass Index 31+5 29 + 6
Diabetes (%) 40 33
No. of antihypertensive
drugs
5.2 + 1.5 5.5 + 1.6
SBP @ baseline in mmHg 178 + 18 174 + 24
DBP @ Baseline in mmHg 97 + 16 92 + 15
HR @ baseline in 1/min 74 69 + 11
SBP @ 6 mths F/U in
mmHg
- 32 + 7 - 23 + 9
DBP @ 6 mths F/U in
mmHg
- 12 +3 -9 + 4
HR @ 6 mth F/U in 1/min 69 64 + 10
SBP @ 12 mths F/U in
mmHg
- 28 + 7 - 20 + 8
DBP @ 12 mths F/U in
mmHg
-10 + 4 -9 + 5
HR @ 12 mths F/U in 1/
min
68 62 + 11
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SBackground: The PARADISE system (ReCor Medical, Menlo Park, CA) is a unique
therapeutic non-focused ultrasound system designed to perform renal denervation
while preventing circumferential damage to the renal artery for resistant hypertension.
The system allows for targeted delivery of ultrasound energy with thermal injury at
depths beyond 0.5 mm while cooling and preserving tissue in its immediate vicinity. A
preclinical porcine animal study was conducted to evaluate the safety and effective-
ness of this technology.
Methods: Renal denervation was performed bilaterally using the PARADISE system
in healthy Yorkshire cross swine (n¼9). Animals were either survived for 7 days, or
sacriﬁced acutely. For the acute study, a standard denervation protocol was used
distally within each renal artery, and for comparison, the same treatment without
cooling was delivered proximally. The arteries were removed, ﬂushed, and stained
with triphenyltetrazolium chloride (TTC) to assess for medial damage. At 7 days,
whole kidney norepinephrine levels were obtained (HPLC-MS) to assess damage to
sympathetic nerves, and histopathologic assessment (H&E) of the renal arteries was
performed to evaluate the integrity of the endothelium, media, and adventitia and
nerve damage was assessed in the perirenal space.
Results: TTC staining of the renal arteries demonstrated non-viable tissue in the
locations where energy was applied without cooling, while standard denervation
treatment with cooling demonstrated preservation of the media. H&E staining
demonstrated minimal to no injury to the endothelium and media at 7 days. Extensive
periadventitial damage was observed with up to 80% nerves damaged within
susceptible zones. Kidney norepinephrine levels were signiﬁcantly reduced in all
animals and correlated with the degree of nerve damage.
Conclusions: The Paradise ultrasound system effectively ablated the sympathetic
nerves surrounding the renal arteries while preserving the media thus demonstrating
the importance of cooling.
TCT-498
Safety and performance of the next generation EnligHTN Renal Denervation
System in patients with drug-resistant, uncontrolled hypertension: a ﬁrst-in-
human multicentre study
Stephen Worthley1, Gerry Wilkins2, Mark W. Webster3, Paul Antonis4,
Roderic Warren5, Robert J. Whitbourn6
1Royal Adelaide Hospital, Adelaide, Australia, 2Dunedin Hospital, Dunedin, New
Zealand, 3Auckland City Hospital, Auckland, New Zealand, 4MonashHeart, Clayton,
Victoria, Australia, 5Royal Melbourne Hospital, Melbourne, Australia,
6Cardiovascular Research Centre, St. Vincent Hospital Melbourne, Melbourne,
Australia
Background: Catheter-based renal artery denervation therapy has become established
as a therapeutic option in patients with resistant hypertension. We have previously
presented safety and efﬁcacy using the ﬁrst generation multi-electrode renal dener-
vation system with the EnligHTN catheter (St. Jude Medical). The next generation
system utilises a novel algorithm for the delivery of 1 minute of radiofrequency
energy, optimised for simultaneous delivery of therapy through all electrodes, with an
interactive generator interface. This study will evaluate the safety and performance of
the next generation EnligHTN Renal Denervation System in patients with drug-
resistant, uncontrolled hypertension.
Methods: Inclusion criteria include patients 18-80 years of age with a systolic BP
160 mmHg and an average daytime systolic ambulatory BP135 mmHg on three or
more antihypertensive agents (including a diuretic). The primary end-points are 1) to
characterize the rate of serious procedural and device related adverse events through 6
months and 2) the change in ofﬁce BP at 6 months. The secondary end-points include
the changes in 24 hour ABP and the characterization of renovascular safety and renal
function change over time. The multi-electrode RF catheter will be introduced in
a renal artery, and RF energy will be delivered simultaneously for 60 seconds across
all 4 electrodes. Next, the catheter will be withdrawn slightly and rotated, and the
denervation sequence will be repeated. This process will then be repeated on the
contralateral renal artery. A minimum of 30 patients will be included in the trial.
Results: To date 10 patients from three sites (63.4  6.4 years, 7M/3F) have been
included. Baseline BP 178.515.2/97.314.0 mmHg, ABPM 159.420.1/87.39.6.
Eight denervations were successfully performed in each artery for all patients. Median
ablation procedure time was 19 min. No vascular or renal artery complications were
observed.
Conclusions: Accumulated results from all sites will be presented at the meeting.
Initial experience suggests that the SJM next generation EnligHTN System may
shorten procedure times while still delivering a safe, predictable and reproducible
denervation pattern.
TCT-499
NT-proBNP reduction correlates with systolic blood pressure decrease in patients
with therapy resistant hypertension undergoing renal denervation (RDN)
Tobias Graf1, Christian Fatum2, Kai Mortensen1, Michael Reppel1, Joachim Weil1
1University of Luebeck, Luebeck, Germany, 2University of Luebeck, Lübeck, Germany
Background: In arterial hypertension risk factor evaluation, including LV mass
measurements and risk stratiﬁcation using risk different charts and scores is usual
practice. In chronic heart failure NT-proBNP has been shown to be a marker of wall
stress and prognosis. Renal denervation (RDN) is a therapeutic strategy for patientsB152 JACC Vol 62/18/Suppl B j Octobwith resistant arterial hypertension. The changes of NT-proBNP in patients under-
going RDN have never been described.
Methods: We investigated 33 patients with resistant hypertension (18 male, 15
female). Inclusion criteria at baseline were a systolic BP 160 mmHg (150 mmHg
in diabetics), treated with 3 antihypertensive drugs, an estimated glomerular ﬁltra-
tion rate 45 mL/min/1.73m2 and suitable renovascular anatomy. Medication was
unchanged during the follow-up period. All patients underwent bilateral RDN.
Systolic (SBP) and diastolic blood (DBP) pressures were measured at baseline and at
the 6 months follow-up with an automated OMRON device. Plasma at baseline and
after 6 months was analyzed for NT-proBNP using the commercially available
Elecsys proBNP sandwich immunoassay on an Elecsys 2010 (Roche Diagnostics,
Mannheim).
Results: (all results are given in meanSEM). Mean age was 63  6 years. Ofﬁce
SBP and DBP were reduced by 20.2  2.5 and 5.8 1.6 mmHg (p<0.01)
after 6 months. Mean NT-proBNP was reduced from 173.4 pg/ml at baseline to
163.4 pg/ml after 6 months (p 0.25) Decrease of systolic blood pressure (SBP)
signiﬁcantly correlates with reduction of NT-proBNP (p 0.01). There was no
signiﬁcant correlation between diastolic blood pressure decrease and NT-proBNP
reduction.
Conclusions: (i) Six months after RDN patients with resistant hypertension experi-
enced a substantial reduction in SBP and DBP. (ii) Systolic blood pressure decrease
correlates with NT-pro-BNP reduction as suggestive marker of reduced LV stress after
successful RDN and signiﬁcant SBP reduction.
TCT-500
Effect of Renal Denervation (RDN) in “Real World” Patients with trHTN
Compared to Simplicity HTN-2 Trial. First Results of the Luebeck RDN Registry
Tobias Graf1, Christian Fatum2, Anne U. Hansen2, Kai Mortensen1, Joachim Weil1
1University of Luebeck, Luebeck, Germany, 2University of Luebeck, Lübeck, Germany
Background: Resistant hypertension is associated with substantially increased risk for
cardiovascular events and mortality. The growing prevalence of hypertension
worldwide (1.6 billion predicted by 2025) combined with an aging population high-
lights the need for effective blood pressure (BP) lowering therapies for patients of all
ages. First data from randomized clinical studies suggest a marked reduction in
systolic (SBP) and diastolic (DBP) 6 month after the procedure. However, there are
limited data out side from clinical trials.
Methods: Data from “real world” patients enrolled in a local RDN program (inclusion
criteria according to Symplicity HTN-2) who completed 12 months follow-up are
compared to data of a controlled clinical trial. All patients had resistant hypertension
deﬁned as a systolic BP (SBP) 160 mm Hg (>150 mmHg in diabetics) while on 3
antihypertensive medications including a diuretic. Demographic data and change from
baseline BP and HR was assessed for each subset at 6 and 12 month.
Results: Table 1Conclusions: The results suggest that RDN performed in a clinical setting has equal
blood pressure lowering effects as when performed in RCT. Furthermore, reduction of
ofﬁce BP and ofﬁce heart rate after renal denervation is consistent under real world
conditions.er 27–November 1, 2013 j TCT Abstracts/POSTER/Renal Denervation
